Cargando…

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

OBJECTIVE: Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year. METHODS: Adults who met ClASsification criteria for Psoriatic ARthritis, with active disease (≥3 swollen and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchlin, Christopher T, Helliwell, Philip S, Boehncke, Wolf-Henning, Soriano, Enrique R, Hsia, Elizabeth C, Kollmeier, Alexa P, Chakravarty, Soumya D, Zazzetti, Federico, Subramanian, Ramanand A, Xu, Xie L, Zuraw, Qing C, Sheng, Shihong, Jiang, Yusang, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Shawi, May, Karyekar, Chetan S, Deodhar, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880108/
https://www.ncbi.nlm.nih.gov/pubmed/33568556
http://dx.doi.org/10.1136/rmdopen-2020-001457